Cefotaxime therapy of serious bacterial infection in adults | Zendy

D. T. Mullaney | Zendy; Joseph F. John | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cefotaxime therapy of serious bacterial infection in adults

Author(s) -

D. T. Mullaney,

Joseph F. John

Publication year - 1982

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.21.3.421

Subject(s) - cefotaxime , minimum inhibitory concentration , medicine , genitourinary system , microbiology and biotechnology , microgram , gastroenterology , adverse effect , antibiotics , in vitro , biology , biochemistry

We evaluated the efficacy, safety, and tolerance of cefotaxime in 35 adults (25 with pleuropulmonary infections, 7 with genitourinary tract infections, and 3 with soft tissue infections). Of these 35 patients, 18 (51.4%) were seriously or critically ill. In vitro susceptibility testing revealed that 90.4% of the pathogens isolated were susceptible to cefotaxime (minimal inhibitory concentration, less than 8 micrograms/ml), 4.8% were intermediately susceptible (minimal inhibitory concentration, 8 to 32 micrograms/ml), and 4.8% were resistant (minimal inhibitory concentration, greater than 32 micrograms/ml). A total of 34 of the 35 patients (97%) were clinically and bacteriologically cured of their infections. Adverse reactions occurred in two patients, but these reactions did not require interruption of therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research